Eton Pharmaceuticals Inc (ETON)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Eton Pharmaceuticals Inc Stock (ETON) Company Profile

Eton Pharmaceuticals Inc

Healthcare (1116)

(847) 787-7361

21925 W. FIELD PARKWAY, DEER PARK, IL

Prossima data di guadagno

Ultimi documenti SEC

ETON's Discussions on Twitter

Compare ETON vs TAK, ZTS, HLN, TEVA, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ETON Eton Pharmaceuticals Inc	18.93	507.66M	70.32M	-6.68M	12.89M	-0.2491
TAK Takeda Pharmaceutical Co Adr	17.77	56.14B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	115.62	48.81B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	10.03	44.67B	14.54B	2.22B	2.58B	0.4879
TEVA Teva Pharmaceutical Industries Ltd Adr	28.57	33.27B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	536.12	23.50B	3.18B	1.33B	1.04B	27.90

Eton Pharmaceuticals Inc Stock (ETON) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-01-23	Reiterato	H.C. Wainwright	Buy
2025-01-10	Iniziato	B. Riley Securities	Buy
2025-01-06	Reiterato	H.C. Wainwright	Buy
2024-09-04	Ripresa	H.C. Wainwright	Buy
2024-05-06	Iniziato	Craig Hallum	Buy
2021-10-14	Ripresa	B. Riley Securities	Buy
2021-01-04	Reiterato	H.C. Wainwright	Buy
2019-09-20	Iniziato	B. Riley FBR	Buy
2019-06-10	Iniziato	H.C. Wainwright	Buy

Mostra tutto

Eton Pharmaceuticals Inc Borsa (ETON) Ultime notizie

Eton Pharmaceuticals Inc Azioni (ETON) Dati Finanziari

Eton Pharmaceuticals Inc (ETON)

Eton Pharmaceuticals Inc Stock (ETON) Company Profile

Compare ETON vs TAK, ZTS, HLN, TEVA, UTHR

Eton Pharmaceuticals Inc Stock (ETON) Upgrades & Downgrades

Eton Pharmaceuticals Inc Borsa (ETON) Ultime notizie

Why (ETON) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Eton Pharmaceuticals (NASDAQ:ETON) Trading Up 6%What's Next? - MarketBeat

Jefferies Financial Group Inc. Invests $1.92 Million in Eton Pharmaceuticals, Inc. $ETON - MarketBeat

Eton Pharmaceuticals (ETON) Expected to Announce Earnings on Thursday - MarketBeat

Chipmakers Recap: Is Eton Pharmaceuticals Inc still a buy after recent gainsWeekly Stock Report & Daily Volume Surge Signals - baoquankhu1.vn

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Consensus Rating of "Hold" by Brokerages - MarketBeat

Will Eton Pharmaceuticals Inc. stock deliver strong dividend growth2026 Rallies & Daily Volume Surge Signals - Naître et grandir

Retail Surge: Can Eton Pharmaceuticals Inc lead its sector in growth2025 Trading Recap & Long-Term Capital Growth Strategies - baoquankhu1.vn

HC Wainwright Analysts Boost Earnings Estimates for ETON - MarketBeat

HC Wainwright Issues Pessimistic Outlook for ETON Earnings - MarketBeat

Eton Pharmaceuticals (NASDAQ:ETON) Given New $30.00 Price Target at Craig Hallum - Defense World

Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026 - The Manila Times

Eton Pharmaceuticals Announces Fourth Quarter and Full Year 2025 Financial Results Date and Conference Call Details - Quiver Quantitative

Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, ... - Bluefield Daily Telegraph

Eton inks deal to sell its 10th rare disease drug - Crain's Chicago Business

Craig Hallum Issues Positive Forecast for Eton Pharmaceuticals (NASDAQ:ETON) Stock Price - MarketBeat

Eton Pharmaceuticals price target raised to $30 from $29 at Craig-Hallum - TipRanks

Eton Pharmaceuticals acquires U.S. rights to hemangioma drug By Investing.com - Investing.com Canada

Eton Pharmaceuticals acquires U.S. rights to hemangioma drug - Investing.com Australia

Eton Gains on Acquiring Right to Baby Medicine - Baystreet.ca

Eton Pharmaceuticals Acquires US Commercialization Rights to Pierre Fabre's Hemangeol - marketscreener.com

HC Wainwright Forecasts Strong Price Appreciation for Eton Pharmaceuticals (NASDAQ:ETON) Stock - MarketBeat

Eton Pharmaceuticals Acquires U.S. Rights to HEMANGEOL - TipRanks

Eton Pharmaceuticals, Inc. announced that, in addition to the acquisition of core assets, the company also plans to purchase approximately $1.5 million worth of inventory products at the time of transaction closing. - Bitget

Eton Pharmaceuticals Secures U.S. Rights to HEMANGEOL® for Infantile Hemangioma Treatment, Launching May 1st - Quiver Quantitative

Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution - The Manila Times

Understanding Momentum Shifts in (ETON) - Stock Traders Daily

Lumbard & Kellner LLC Buys New Holdings in Eton Pharmaceuticals, Inc. $ETON - MarketBeat

Eton Pharmaceuticals Expands Rare Disease Portfolio Through - GlobeNewswire

Eton Pharmaceuticals (NASDAQ: ETON) licenses U.S. HEMANGEOL rights in orphan drug deal - Stock Titan

Eton Pharmaceuticals, Inc. has signed a licensing agreement to successfully acquire the exclusive U.S. marketing rights for Hemangeol oral solution from Pierre Fabre Medicament Sas. - Bitget

Eton Pharmaceuticals' DESMODA Receives FDA Approval - Intellectia AI

US FDA approves Eton Pharma’s hormonal disorder drug - 1470 & 100.3 WMBD

Eton Pharmaceuticals Receives FDA Approval for New Drug Launch - Intellectia AI

Eton Reports US FDA Approval for Desmoda Oral Solution - marketscreener.com

Eton Pharmaceuticals Wins FDA Approval for DESMODA Therapy - TipRanks

Eton wins FDA nod for rare disorder therapy Desmoda (ETON) - Seeking Alpha

US FDA approves Eton's liquid therapy for rare water-balance disorder - Reuters

US FDA approves Eton Pharma's hormonal disorder drug - AOL.com

Eton Pharmaceuticals Launches DESMODA™, First FDA-Approved Oral Solution for Central Diabetes Insipidus - Quiver Quantitative

Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution - GlobeNewswire

ETON Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

FDA To Decide On ET-600 On February 25: Will It Mark Eton's Ninth Commercial Product? - RTTNews

Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th - The Manila Times

February 2026's Top Growth Companies With Insider Influence - simplywall.st

Eton Pharmaceuticals submits NDA for its diabetes insipidus treatment - MSN

What are Eton Pharmaceuticals Inc.’s technical support levelsJuly 2025 Big Picture & Real-Time Stock Entry Alerts - mfd.ru

Volatility Watch: Is Eton Pharmaceuticals Inc a cyclical or defensive stockGap Up & Safe Entry Zone Identification - baoquankhu1.vn

Activity Recap: Is Eton Pharmaceuticals Inc. still a buy after recent gains - mfd.ru

Eton Pharmaceuticals (ETON) Investor Outlook: A Small-Cap Biotech with a 78.68% Potential Upside - DirectorsTalk Interviews

What drives Eton Pharmaceuticals Inc.’s stock priceEarnings Miss & Weekly High Potential Stock Alerts - mfd.ru

Eton Pharmaceuticals Inc Azioni (ETON) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a ETON